Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment

Stage II colorectal cancer(CRC) patients after surgery alone have a five-year survival rate of ~60-80%; the incremental benefit of adjuvant chemotherapy is

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-03, Vol.14, p.1103741-1103741
Main Authors: Wang, Fulong, Lu, Shixun, Zhou, Xin, Di, Xiaotang, Wu, Rujia, Chen, Gong, Tian, Sun
Format: Article
Language:English
Subjects:
Colorectal Neoplasms - drug therapy
formalin-fixed paraffin-embedded samples (FFPE samples)
Humans
Immunology
Neoplasm Staging
personalized adjuvant drugs
personalized immunotherapy
Precision Medicine
prognosis prediction
Risk Factors
stage II colorectal cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stage II colorectal cancer(CRC) patients after surgery alone have a five-year survival rate of ~60-80%; the incremental benefit of adjuvant chemotherapy is
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1103741